Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer - PubMed (original) (raw)
Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer
Sherry X Yang et al. Clin Cancer Res. 2008.
Abstract
Purpose: To identify biomarkers and gene expression profile signatures to distinguish patients with partial response (PR) from those with stable disease (SD) and progressive disease (PD).
Experimental design: Twenty patients with inflammatory breast cancer and one patient with locally advanced breast cancer received one cycle of bevacizumab followed by six cycles of bevacizumab plus docetaxel-doxorubicin before surgery. Baseline angiogenic/tumor markers were examined by immunohistochemistry and gene expression profiles were measured by Agilent Whole Human Genome arrays. All were assessed for clinical response.
Results: Fourteen patients (67%, 95% confidence interval, 43-85.4%) had PR, five had SD, and two had PD. Expression of CD31 and platelet-derived growth factor receptor-beta (PDGFR-beta) in the tumor vasculature by immunohistochemistry was significantly associated with response (PR versus SD/PD; CD31 median, 33.5 versus 13.2; P = 0.0004; PDGFR-beta median, 5.9 versus 0.6; P = 0.01). Tumor VEGF-A showed a trend towards association with response (2.65 versus 0.25; P = 0.04). pVEGFR2(Y996), pVEGFR2(Y951), MVD, Ki67, apoptosis, grade, ER, HER-2/neu, and p53 were not associated with response. Twenty-six of 1,339 Gene Ontology (GO) classes at the gene transcriptional level were differentially expressed between patients with PR and SD/PD (P < 0.005). Representative significant GO classes include spindle (11 genes; P = 0.001), vascular endothelial growth factor receptor activity including PDGFR-beta (5 genes; P = 0.002), and cell motility including CD31 (80 genes; P = 0.005).
Conclusions: Baseline CD31, PDGFR-beta, and GO classes for vascular endothelial growth factor receptor activity and mitosis were significantly associated with response to bevacizumab followed by bevacizumab plus chemotherapy.
Figures
Fig.1
Expression of CD31, PDGFR-β and tumor VEGF-A in representative patient tumor biopsies. There were high levels of CD31 (A) and VEGF-A (C), and PDGFR-β (E) in tumor biopsy sections from a patient with PR compared to low levels of CD31 (B) and tumor VEGF-A (D) in those from a patient with PD or low level of PDGFR-β (F) in the section from a patient with SD. PR, partial response; PD, progressive disease; SD, stable disease.
Fig. 2
The change in CD31 expression after BV treatment alone in patients with IBC and LABC. Shown was the relative change in CD31 expression in the tumor vasculature in 15 patients that paired biopsies were available for analysis. Pt, patient; BV, bevacizumab.
Comment in
- Biomarkers and response to therapy in breast cancer.
Jubb AM. Jubb AM. Clin Cancer Res. 2009 Jan 1;15(1):414; author reply 414-5. doi: 10.1158/1078-0432.CCR-08-2404. Clin Cancer Res. 2009. PMID: 19118076 No abstract available.
Similar articles
- p53, HER2 and tumor cell apoptosis correlate with clinical outcome after neoadjuvant bevacizumab plus chemotherapy in breast cancer.
Yang SX, Steinberg SM, Nguyen D, Swain SM. Yang SX, et al. Int J Oncol. 2011 May;38(5):1445-52. doi: 10.3892/ijo.2011.966. Epub 2011 Mar 9. Int J Oncol. 2011. PMID: 21399868 Free PMC article. - A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers.
Baar J, Silverman P, Lyons J, Fu P, Abdul-Karim F, Ziats N, Wasman J, Hartman P, Jesberger J, Dumadag L, Hohler E, Leeming R, Shenk R, Chen H, McCrae K, Dowlati A, Remick SC, Overmoyer B. Baar J, et al. Clin Cancer Res. 2009 May 15;15(10):3583-90. doi: 10.1158/1078-0432.CCR-08-2917. Epub 2009 May 5. Clin Cancer Res. 2009. PMID: 19417018 Free PMC article. Clinical Trial. - High-circulating Tie2 Is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer.
Makhoul I, Griffin RJ, Siegel E, Lee J, Dhakal I, Raj V, Jamshidi-Parsian A, Klimberg S, Hutchins LF, Kadlubar S. Makhoul I, et al. Am J Clin Oncol. 2016 Jun;39(3):248-54. doi: 10.1097/COC.0000000000000046. Am J Clin Oncol. 2016. PMID: 24577164 Free PMC article. Clinical Trial. - Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.
Chan A, Miles DW, Pivot X. Chan A, et al. Ann Oncol. 2010 Dec;21(12):2305-2315. doi: 10.1093/annonc/mdq122. Epub 2010 Mar 24. Ann Oncol. 2010. PMID: 20335367 Review. - Bevacizumab for advanced breast cancer.
Goldfarb SB, Traina TA, Dickler MN. Goldfarb SB, et al. Womens Health (Lond). 2010 Jan;6(1):17-25. doi: 10.2217/whe.09.71. Womens Health (Lond). 2010. PMID: 20001867 Review.
Cited by
- The genomic and transcriptome characteristics of lung adenocarcinoma patients with previous breast cancer.
Wang Y, Song W, Zhou S, Chang S, Chang J, Tian J, Zhang L, Li J, Che G. Wang Y, et al. BMC Cancer. 2022 Jun 6;22(1):618. doi: 10.1186/s12885-022-09727-6. BMC Cancer. 2022. PMID: 35668376 Free PMC article. - Predictive value of microvessel features for the clinical response to neoadjuvant chemotherapy in cervical squamous carcinoma and the associations with prognosis.
Li W, Liang C, Liu P, Qi Y, Shen H, Li M, Chen C. Li W, et al. Transl Cancer Res. 2021 Jan;10(1):162-173. doi: 10.21037/tcr-20-2741. Transl Cancer Res. 2021. PMID: 35116248 Free PMC article. - Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer.
Krüger K, Silwal-Pandit L, Wik E, Straume O, Stefansson IM, Borgen E, Garred Ø, Naume B, Engebraaten O, Akslen LA. Krüger K, et al. Sci Rep. 2021 Feb 9;11(1):3388. doi: 10.1038/s41598-021-81914-0. Sci Rep. 2021. PMID: 33564016 Free PMC article. Clinical Trial. - In-silico network-based analysis of drugs used against COVID-19: Human well-being study.
Attique Z, Ali A, Hamza M, Al-Ghanim KA, Mehmood A, Khan S, Ahmed Z, Al-Mulhm N, Rizwan M, Munir A, Al-Suliman E, Farooq M, F AM, Mahboob S. Attique Z, et al. Saudi J Biol Sci. 2021 Mar;28(3):2029-2039. doi: 10.1016/j.sjbs.2021.01.006. Epub 2021 Jan 21. Saudi J Biol Sci. 2021. PMID: 33519272 Free PMC article. - Personalized chemotherapy in clear cell adenocarcinoma of the urethra: A case report.
Shields LBE, Kalebasty AR. Shields LBE, et al. World J Clin Oncol. 2020 Apr 24;11(4):243-249. doi: 10.5306/wjco.v11.i4.243. World J Clin Oncol. 2020. PMID: 32355644 Free PMC article.
References
- Low JA, Berman AW, Steinberg SM, et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol. 2004;22:4067–74. - PubMed
- McCarthy NJ, Yang X, Linnoila IR, et al. Microvessel density, expression of estrogen receptor alpha, mib-1, p53, and c-erbb-2 in inflammatory breast cancer. Clin Cancer Res. 2002;8:3857–62. - PubMed
- Ranieri G, Patruno R, Ruggieri E, et al. Vascular endothelial growth factor (vegf) as a target of bevacizumab in cancer: From the biology to the clinic. Curr Med Chem. 2006;13:1845–57. - PubMed
- Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666–76. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous